Consistent with DDX21, high MCM5 expression predicts poor OS rate and DFS rate in stage III and IV CRC patients (Fig. S6A, D), rather than among all stage or stage I and II (Fig. S6B, C, E, F). This evidence concerns the gene MCM5 and colorectal carcinoma.